ABC: Children with COVID-19 are at risk of a rare complication. Will Omicron make MIS-C more common?
Paediatricians flag a surge in paediatric inflammatory multisystem syndrome following COVID-19 infection, with more than 6,000 cases reported in the US and 35 in Australia. PIMS-TS is most common in children around the age of 9, weeks after they’ve experienced a mild or asymptomatic case of COVID-19. Currently, doctors have not been able to identify an exact causal effect, but some scientists believe a child’s body can have a delayed reaction to the virus.
“We are getting much better now at recognising the syndrome and treating it” explains Associate Professor Nigel Crawford.
While this complication is very rare, scientists are currently uncertain whether the highly infectious Omicron variant will perpetuate a spike in PIMS-TS occurrences.
请点击以下链接阅读全文：
Children with COVID-19 are at risk of a rare complication. Will Omicron make MIS-C more common?
ATAGI Statement on the use of Novavax COVID-19 vaccine (Nuvaxovid)
Following two phase lll clinical trials conducted in the USA/Mexico and in the UK, the Therapeutic Goods Administration (TGA) has granted provisional approval of the Novavvax COVID-19 vaccine in Australia.
Novavax COVID-19 vaccine, also known as Nuvaxovid (Biocelect Pty Ltd/Novavax Inc) is a spike protein-based vaccine with each 0.5mL dose containing 5 micrograms of the of SARS-CoV-2 spike protein and 50 micrograms of Matrix-M as an adjuvant.
Novavax COVID-19 vaccine demonstrated to be highly effective in preventing symptomatic COVID-19 disease in adults in a primary schedule. ATAGI continues to monitor the safety, efficacy and immunogenicity data of Novavax COVID-19 vaccine including in high-risk priority groups and will provide updated recommendations as required.
To read the full ATAGI statement, follow the link below:
ATAGI Statement on the use of Novavax COVID-19 vaccine (Nuvaxovid)
ABC: Should I mix or match my booster? Your COVID-19 vaccine questions answered
ATAGI recommends that everyone aged 18 years and over to receive a booster dose of the Pfizer or Moderna COVID-19 vaccine, regardless of which vaccine they received for their primary course.
With over 5 million people now triple jabbed, Australia’s COVID-19 booster rollout is well underway.
This article explores some of the clinical data and considerations regarding the COVID-19 boosters.
To read the full article, follow the link below.
Should I mix or match my booster? Your COVID-19 vaccine questions answered
WHO: 2021 has been tumultuous but we know how to end the pandemic and promote health for all in 2022
In 2021, the global health system faced significant challenges perpetuated by the ongoing COVID-19 pandemic. Proving that when health is at risk, everything is at risk. However, there have still been medical breakthroughs and progress including new COVID-19 treatments, the introduction of the world’s first malaria vaccine and the near eradication of polio disease.
The year 2022 brings a hopeful glimpse to end the COVID-19 pandemic, through countries working together, pushing for greater vaccine equity to reach a 70% global vaccination rate.
In this article, the WHO reflects on the challenges and triumphs of the global health system throughout 2021 and outlines some positive opportunities for the coming new year.
To read the full article, follow the link below.
2021 has been tumultuous but we know how to end the pandemic and promote health for all in 2022
澳大利亚免疫技术咨询小组 (ATAGI) 关于使用 Spikevax (Moderna) 作为 COVID-19 加强疫苗的建议
在最近获得 TGA 的批准后， 澳大利亚免疫技术咨询小组 (ATAGI) 已推荐 使用 Spikevax (Moderna) 作为 COVID-19 加强疫苗，适用于 5 个月或更长时间前完成 COVID-19 疫苗初级课程的 18 岁及以上人群（包括孕妇）。加强剂量是用于初级课程的 Spikevax 疫苗推荐剂量的一半。
ATAGI 指出，Moderna 和辉瑞公司的 COVID-19 疫苗在澳大利亚的合格人群中同样可以用作加强疫苗。
To read ATAGI's 关于使用 Moderna COVID-19 疫苗作为加强剂的完整声明如下 下面的链接:
澳大利亚免疫技术咨询小组 (ATAGI) 关于使用 Spikevax (Moderna) 作为 COVID-19 加强疫苗的建议
The Conversation: How can scientists update coronavirus vaccines for omicron? A microbiologist answers 5 questions about how Moderna and Pfizer could rapidly adjust mRNA vaccines
The new Omicron variant has raised the question of whether current COVID-19 vaccines will provide sufficient protection against infection. If the virus has changed significantly, antibodies created by the original vaccine will no longer be able to recognise and defend against the new mutated variant. Consequentially, vaccines will need to be modified by swapping out the genetic code of the original spike protein for the one found on the new variant.
This article explores the scientific process behind updating mRNA vaccines including timelines and authorization procedures.
请点击以下链接阅读全文：
Australian Academy of Science: COVID-19 vaccines and their long-term safety
Getting vaccinated against COVID-19 is the best way to protect ourselves and our communities. Current data and evidence confidently support the long term safety of COVID-19 vaccines.
This article discusses the various safety processes currently in place for COVID-19 vaccines to ensure that they continue to be effective in preventing severe disease.
To read the article in full, click on the link below:
COVID-19 vaccines and their long-term safety
The Conversation: Nose sprays, needle-free patches, durable immunity: towards the next generation of COVID vaccination
The COVID-19 pandemic has perpetuated rapid medical advancements and technological innovations. Over the last 20 months, we’ve experienced an influx of new vaccines which have proven to be safe and effective in preventing disease.
Scientists and researchers around the world are already working on the next generation of COVID vaccines to help tackle issues regarding waning immunity, storage and delivery, and vaccine hesitancy. Focusing their efforts on making vaccination easier, delivering more durable immunity and protecting against future variants
This article looks at the different considerations for research and technology around the world that will in turn lead to the next generation of COVID vaccines.
Follow the link to read the full article: Nose sprays, needle-free patches, durable immunity: towards the next generation of COVID vaccination
Raising Children Network - new COVID-19 vaccination resource for teenagers
MVEC has partnered with the 育儿网 to develop a new resource focused on providing COVID-19 vaccine recommendations for immunising teenagers, 12 years and over.
This article addresses key factors for immunising teens, including doses, safety, efficacy, side effects and how to cope with needle phobia.
To view this article follow the link below:
COVID-19 vaccination and teenagers
More information on COVID-19 vaccines for children and teens can be found via our immunisation reference page below:
MVEC: COVID-19 vaccination in children
MVEC 播客系列 - COVID-19 疫苗
随着 2020 年接近尾声，人们乐观地认为，安全有效的 SARS-CoV-2 (COVID-19) 疫苗将很快获得批准，以控制大流行。目前全球有 200 多种候选疫苗处于临床试验的各个阶段，澳大利亚已与 4 种不同的疫苗签署了预购协议。
在我们的 COVID-19 疫苗 3 部分视频广播系列中，Daryl Cheng 博士和 Daniela Say 博士讨论了如何在如此紧迫的时间内开发疫苗、临床试验中使用的各种疫苗平台及其各自的优缺点，以及要提供免疫接种的不同优先群体。 Daryl 和 Daniela 谈到了临床试验的初步结果以及它们在疫苗安全性和有效性方面向我们展示的内容，并讨论了即使疫苗获准使用也会进行的持续安全监测。
您可以通过以下链接查看播客：